Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Xiayang Ren"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Combining immune checkpoint and proton pump inhibitors is widely used in cancer treatment. However, the drug-drug interactions of these substances are currently unknown. This study aimed to explore drug-drug interactions associate
Externí odkaz:
https://doaj.org/article/5fe85e835f69445692ad453ca97b9064
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Antibody–drug conjugates (ADCs) are among the fastest-growing classes of anticancer drugs, making it crucial to evaluate their potential for causing peripheral neuropathy. We analyzed data from the FAERS database (January 1, 2014, to June
Externí odkaz:
https://doaj.org/article/0dc9a68f77c24efbaf864cb9aac608c8
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Nervous system toxicity (NST) is one of the most frequent and dangerous side effects of chimeric antigen receptor T-cell (CAR-T) therapy, which is an effective treatment for related tumors in most relapsed/refractory (r/r) hematol
Externí odkaz:
https://doaj.org/article/9ed810b791384fb6a1a1ffb8692cbda2
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundImmune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors (AGIs) have become increasingly available for multiple types of cancers, although the cardiovascular safety profiles of this combination therapy in real-world setting
Externí odkaz:
https://doaj.org/article/cc937839699a4baab3c754baa3a4b42d
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundThe profiles of cardiovascular toxicity associated with angiogenesis inhibitors, including intravenous monoclonal antibodies (mAbs) and oral tyrosine kinase inhibitors (TKIs), targeting vascular endothelial growth factor (VEGF) remain poorl
Externí odkaz:
https://doaj.org/article/2b420b6e8fd54a57b9f03faec0f44e8f
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundImmune checkpoint inhibitors (ICIs), the treatment of multiple cancer types, can be associated with respiratory system adverse events (AEs). The aim of this study is to quantify the association of respiratory system AEs and ICIs and to char
Externí odkaz:
https://doaj.org/article/942dbf95d9f54aa18b4059153280c54d
Publikováno v:
International journal of immunopathology and pharmacology. 36
Objective The haematopoietic cytopenia (HC) of the cyclin-dependent kinase (CDK)4/6 inhibitors was evaluated using the Food and Drug Administration Adverse Event Reporting System (FAERS). Method Data from 1 January 2015 to 31 December 2021 has been r
Purpose This study further approaches immune-related interstitial lung disease adverse event (AE) in patients undergoing immune checkpoint inhibitor (ICI) monotherapy, ICI plus chemotherapy and ICI plus anti-VEGF therapy in the postmarketing period.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::315cf7f52f446d842174ae397f55c8db
https://doi.org/10.21203/rs.3.rs-2023720/v1
https://doi.org/10.21203/rs.3.rs-2023720/v1
Publikováno v:
European Journal of Pharmacology. 946:175561
Purpose. The management of outpatients with cancer painis very important for medication safety. Medical interviews by CP is conducive to pain management. Our objective was to describe the contribution of the clinical pharmacist (CP) to outpatients in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6f22d57075acbcbcd2f7fa579735d02
https://doi.org/10.21203/rs.3.rs-561174/v1
https://doi.org/10.21203/rs.3.rs-561174/v1